An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies (2018–2024)
- Grant type:
- NHMRC MRFF - Lifting Clinical Trials Registries Capacity
- Researchers:
-
-
Director, MRI & CEO Mater(Conjoint)
Mater Research Institute-UQFaculty of Medicine -
-
- Funded by:
- Commonwealth Department of Health and Aged Care
